What ||| S:0 E:4 ||| WP
's  ||| S:4 E:7 ||| VBZ
new  ||| S:7 E:11 ||| JJ
in  ||| S:11 E:14 ||| IN
internal  ||| S:14 E:23 ||| JJ
medicine ||| S:23 E:31 ||| NN
:  ||| S:31 E:33 ||| :
emerging  ||| S:33 E:42 ||| VBG
treatments  ||| S:42 E:53 ||| NNS
for  ||| S:53 E:57 ||| IN
systemic  ||| S:57 E:66 ||| JJ
lupus  ||| S:66 E:72 ||| JJ
erythematosus  ||| S:72 E:86 ||| JJ
Today  ||| S:86 E:92 ||| NN
corticosteroids  ||| S:92 E:108 ||| NNS
plus  ||| S:108 E:113 ||| CC
hydroxychloroquine  ||| S:113 E:132 ||| NNS
are  ||| S:132 E:136 ||| VBP
the  ||| S:136 E:140 ||| DT
cornerstone  ||| S:140 E:152 ||| NN
in  ||| S:152 E:155 ||| IN
the  ||| S:155 E:159 ||| DT
treatment  ||| S:159 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
Systemic  ||| S:172 E:181 ||| NNP
Lupus  ||| S:181 E:187 ||| NNP
Erythematosus  ||| S:187 E:201 ||| NNP
( ||| S:201 E:202 ||| -LRB-
SLE ||| S:202 E:205 ||| NNP
) ||| S:205 E:206 ||| -RRB-
.  ||| S:206 E:208 ||| .
In  ||| S:208 E:211 ||| IN
severe  ||| S:211 E:218 ||| JJ
cases ||| S:218 E:223 ||| NNS
,  ||| S:223 E:225 ||| ,
particularly  ||| S:225 E:238 ||| RB
in  ||| S:238 E:241 ||| IN
proliferative  ||| S:241 E:255 ||| JJ
glomerulonephritis ||| S:255 E:273 ||| NN
,  ||| S:273 E:275 ||| ,
cyclophosphamide  ||| S:275 E:292 ||| NN
or  ||| S:292 E:295 ||| CC
mycofenolate  ||| S:295 E:308 ||| JJ
mofetil  ||| S:308 E:316 ||| NNS
are  ||| S:316 E:320 ||| VBP
used  ||| S:320 E:325 ||| VBN
in  ||| S:325 E:328 ||| IN
induction  ||| S:328 E:338 ||| NN
and  ||| S:338 E:342 ||| CC
mycofenolate  ||| S:342 E:355 ||| JJ
mofetil  ||| S:355 E:363 ||| NN
or  ||| S:363 E:366 ||| CC
azathioprine  ||| S:366 E:379 ||| NNS
are  ||| S:379 E:383 ||| VBP
used  ||| S:383 E:388 ||| VBN
to  ||| S:388 E:391 ||| TO
maintain  ||| S:391 E:400 ||| VB
the  ||| S:400 E:404 ||| DT
remission ||| S:404 E:413 ||| NN
.  ||| S:413 E:415 ||| .
Corticosteroid  ||| S:415 E:430 ||| JJ
sparing  ||| S:430 E:438 ||| NN
is  ||| S:438 E:441 ||| VBZ
an  ||| S:441 E:444 ||| DT
important  ||| S:444 E:454 ||| JJ
goal ||| S:454 E:458 ||| NN
.  ||| S:458 E:460 ||| .
New  ||| S:460 E:464 ||| NNP
and  ||| S:464 E:468 ||| CC
future  ||| S:468 E:475 ||| JJ
treatments  ||| S:475 E:486 ||| NNS
of  ||| S:486 E:489 ||| IN
SLE  ||| S:489 E:493 ||| NNP
focus  ||| S:493 E:499 ||| NN
on  ||| S:499 E:502 ||| IN
B  ||| S:502 E:504 ||| NNP
and  ||| S:504 E:508 ||| CC
T  ||| S:508 E:510 ||| NN
cells  ||| S:510 E:516 ||| NNS
down  ||| S:516 E:521 ||| IN
regulation  ||| S:521 E:532 ||| NN
and  ||| S:532 E:536 ||| CC
co-stimulation ||| S:536 E:550 ||| JJ
,  ||| S:550 E:552 ||| ,
cytokine  ||| S:552 E:561 ||| JJ
inhibition ||| S:561 E:571 ||| NN
,  ||| S:571 E:573 ||| ,
and  ||| S:573 E:577 ||| CC
open  ||| S:577 E:582 ||| VB
the  ||| S:582 E:586 ||| DT
concept  ||| S:586 E:594 ||| NN
of  ||| S:594 E:597 ||| IN
immune  ||| S:597 E:604 ||| JJ
vaccination ||| S:604 E:615 ||| NN
.  ||| S:615 E:617 ||| .
However ||| S:617 E:624 ||| RB
,  ||| S:624 E:626 ||| ,
positive  ||| S:626 E:635 ||| JJ
phase  ||| S:635 E:641 ||| NN
III  ||| S:641 E:645 ||| NNP
randomized  ||| S:645 E:656 ||| NN
studies  ||| S:656 E:664 ||| NNS
in  ||| S:664 E:667 ||| IN
SLE  ||| S:667 E:671 ||| NNP
remain  ||| S:671 E:678 ||| VBP
rare ||| S:678 E:682 ||| JJ
.  ||| S:682 E:684 ||| .
Rituximab  ||| S:684 E:694 ||| NNP
( ||| S:694 E:695 ||| -LRB-
a  ||| S:695 E:697 ||| DT
chimeric  ||| S:697 E:706 ||| JJ
monoclonal  ||| S:706 E:717 ||| JJ
anti-CD  ||| S:717 E:725 ||| JJ
20  ||| S:725 E:728 ||| CD
antibody ||| S:728 E:736 ||| NN
)  ||| S:736 E:738 ||| -RRB-
was  ||| S:738 E:742 ||| VBD
the  ||| S:742 E:746 ||| DT
first  ||| S:746 E:752 ||| JJ
promising  ||| S:752 E:762 ||| JJ
biologic  ||| S:762 E:771 ||| JJ
agent  ||| S:771 E:777 ||| NN
showing  ||| S:777 E:785 ||| VBG
interesting  ||| S:785 E:797 ||| JJ
results  ||| S:797 E:805 ||| NNS
in  ||| S:805 E:808 ||| IN
large  ||| S:808 E:814 ||| JJ
case  ||| S:814 E:819 ||| NN
series  ||| S:819 E:826 ||| NN
but  ||| S:826 E:830 ||| CC
2  ||| S:830 E:832 ||| CD
phases  ||| S:832 E:839 ||| NNS
III  ||| S:839 E:843 ||| NNP
randomised  ||| S:843 E:854 ||| NN
studies  ||| S:854 E:862 ||| NNS
did ||| S:862 E:865 ||| VBD
n't  ||| S:865 E:869 ||| RB
reach  ||| S:869 E:875 ||| VB
their  ||| S:875 E:881 ||| PRP$
primary  ||| S:881 E:889 ||| JJ
objective ||| S:889 E:898 ||| NN
.  ||| S:898 E:900 ||| .
This  ||| S:900 E:905 ||| DT
probably  ||| S:905 E:914 ||| RB
emphasizes  ||| S:914 E:925 ||| VBZ
the  ||| S:925 E:929 ||| DT
limit  ||| S:929 E:935 ||| NN
of  ||| S:935 E:938 ||| IN
the  ||| S:938 E:942 ||| DT
current  ||| S:942 E:950 ||| JJ
tools  ||| S:950 E:956 ||| NNS
used  ||| S:956 E:961 ||| VBN
for  ||| S:961 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
evaluation  ||| S:969 E:980 ||| NN
of  ||| S:980 E:983 ||| IN
the  ||| S:983 E:987 ||| DT
disease  ||| S:987 E:995 ||| NN
and  ||| S:995 E:999 ||| CC
point  ||| S:999 E:1005 ||| NN
out  ||| S:1005 E:1009 ||| IN
the  ||| S:1009 E:1013 ||| DT
design  ||| S:1013 E:1020 ||| NN
of  ||| S:1020 E:1023 ||| IN
the  ||| S:1023 E:1027 ||| DT
studies  ||| S:1027 E:1035 ||| NNS
using  ||| S:1035 E:1041 ||| VBG
high  ||| S:1041 E:1046 ||| JJ
dose  ||| S:1046 E:1051 ||| NN
of  ||| S:1051 E:1054 ||| IN
corticosteroids ||| S:1054 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
immunosuppressive  ||| S:1071 E:1089 ||| JJ
drugs  ||| S:1089 E:1095 ||| NNS
and  ||| S:1095 E:1099 ||| CC
the  ||| S:1099 E:1103 ||| DT
use  ||| S:1103 E:1107 ||| NN
of  ||| S:1107 E:1110 ||| IN
rituximab  ||| S:1110 E:1120 ||| VBG
as  ||| S:1120 E:1123 ||| RB
add  ||| S:1123 E:1127 ||| VB
on  ||| S:1127 E:1130 ||| IN
treatment  ||| S:1130 E:1140 ||| NN
and  ||| S:1140 E:1144 ||| CC
are  ||| S:1144 E:1148 ||| VBP
not  ||| S:1148 E:1152 ||| RB
face  ||| S:1152 E:1157 ||| VB
to  ||| S:1157 E:1160 ||| TO
face  ||| S:1160 E:1165 ||| VB
with  ||| S:1165 E:1170 ||| IN
conventional  ||| S:1170 E:1183 ||| JJ
treatment ||| S:1183 E:1192 ||| NN
.  ||| S:1192 E:1194 ||| .
Abatacept  ||| S:1194 E:1204 ||| NNP
( ||| S:1204 E:1205 ||| -LRB-
CTLA4-Ig ||| S:1205 E:1213 ||| NNP
)  ||| S:1213 E:1215 ||| -RRB-
also  ||| S:1215 E:1220 ||| RB
failed  ||| S:1220 E:1227 ||| VBN
to  ||| S:1227 E:1230 ||| TO
meet  ||| S:1230 E:1235 ||| VB
its  ||| S:1235 E:1239 ||| PRP$
primary  ||| S:1239 E:1247 ||| JJ
end  ||| S:1247 E:1251 ||| NN
point  ||| S:1251 E:1257 ||| NN
in  ||| S:1257 E:1260 ||| IN
a  ||| S:1260 E:1262 ||| DT
randomised  ||| S:1262 E:1273 ||| JJ
controlled  ||| S:1273 E:1284 ||| JJ
trial  ||| S:1284 E:1290 ||| NN
in  ||| S:1290 E:1293 ||| IN
non-nephritis  ||| S:1293 E:1307 ||| NNP
SLE ||| S:1307 E:1310 ||| NNP
.  ||| S:1310 E:1312 ||| .
A  ||| S:1312 E:1314 ||| DT
post-hoc  ||| S:1314 E:1323 ||| JJ
analysis  ||| S:1323 E:1332 ||| NN
suggests  ||| S:1332 E:1341 ||| VBZ
however  ||| S:1341 E:1349 ||| RB
that  ||| S:1349 E:1354 ||| IN
abatacept  ||| S:1354 E:1364 ||| NNS
may  ||| S:1364 E:1368 ||| MD
be  ||| S:1368 E:1371 ||| VB
beneficial  ||| S:1371 E:1382 ||| JJ
in  ||| S:1382 E:1385 ||| IN
lupus  ||| S:1385 E:1391 ||| JJ
patients  ||| S:1391 E:1400 ||| NNS
with  ||| S:1400 E:1405 ||| IN
arthritis  ||| S:1405 E:1415 ||| NN
however ||| S:1415 E:1422 ||| RB
,  ||| S:1422 E:1424 ||| ,
it  ||| S:1424 E:1427 ||| PRP
will  ||| S:1427 E:1432 ||| MD
probably  ||| S:1432 E:1441 ||| RB
never  ||| S:1441 E:1447 ||| RB
be  ||| S:1447 E:1450 ||| VB
approved  ||| S:1450 E:1459 ||| VBN
for  ||| S:1459 E:1463 ||| IN
that  ||| S:1463 E:1468 ||| DT
indication ||| S:1468 E:1478 ||| NN
.  ||| S:1478 E:1480 ||| .
Belimumab  ||| S:1480 E:1490 ||| NNP
( ||| S:1490 E:1491 ||| -LRB-
a  ||| S:1491 E:1493 ||| DT
human  ||| S:1493 E:1499 ||| JJ
monoclonal  ||| S:1499 E:1510 ||| JJ
antibody  ||| S:1510 E:1519 ||| NN
to  ||| S:1519 E:1522 ||| TO
BLyS ||| S:1522 E:1526 ||| NNP
)  ||| S:1526 E:1528 ||| -RRB-
is  ||| S:1528 E:1531 ||| VBZ
the  ||| S:1531 E:1535 ||| DT
first  ||| S:1535 E:1541 ||| JJ
biologic  ||| S:1541 E:1550 ||| JJ
agent  ||| S:1550 E:1556 ||| NN
which  ||| S:1556 E:1562 ||| WDT
reached  ||| S:1562 E:1570 ||| VBD
its  ||| S:1570 E:1574 ||| PRP$
primary  ||| S:1574 E:1582 ||| JJ
end  ||| S:1582 E:1586 ||| NN
point  ||| S:1586 E:1592 ||| NN
in  ||| S:1592 E:1595 ||| IN
2  ||| S:1595 E:1597 ||| CD
different  ||| S:1597 E:1607 ||| JJ
randomised  ||| S:1607 E:1618 ||| NNS
controlled  ||| S:1618 E:1629 ||| VBN
trials  ||| S:1629 E:1636 ||| NNS
using  ||| S:1636 E:1642 ||| VBG
a  ||| S:1642 E:1644 ||| DT
new  ||| S:1644 E:1648 ||| JJ
index  ||| S:1648 E:1654 ||| NN
for  ||| S:1654 E:1658 ||| IN
the  ||| S:1658 E:1662 ||| DT
evaluation  ||| S:1662 E:1673 ||| NN
of  ||| S:1673 E:1676 ||| IN
the  ||| S:1676 E:1680 ||| DT
activity  ||| S:1680 E:1689 ||| NN
of  ||| S:1689 E:1692 ||| IN
the  ||| S:1692 E:1696 ||| DT
diseases  ||| S:1696 E:1705 ||| NNS
taking  ||| S:1705 E:1712 ||| VBG
into  ||| S:1712 E:1717 ||| IN
account  ||| S:1717 E:1725 ||| NN
the  ||| S:1725 E:1729 ||| DT
physicians  ||| S:1729 E:1740 ||| JJ
judgement  ||| S:1740 E:1750 ||| NNS
( ||| S:1750 E:1751 ||| -LRB-
SLE  ||| S:1751 E:1755 ||| NNP
responder  ||| S:1755 E:1765 ||| JJ
index ||| S:1765 E:1770 ||| NN
) ||| S:1770 E:1771 ||| -RRB-
.  ||| S:1771 E:1773 ||| .
Lots  ||| S:1773 E:1778 ||| NNS
of  ||| S:1778 E:1781 ||| IN
phase  ||| S:1781 E:1787 ||| NN
I ||| S:1787 E:1788 ||| PRP
/ ||| S:1788 E:1789 ||| VBZ
II  ||| S:1789 E:1792 ||| NNP
studies  ||| S:1792 E:1800 ||| NNS
are  ||| S:1800 E:1804 ||| VBP
currently  ||| S:1804 E:1814 ||| RB
ongoing  ||| S:1814 E:1822 ||| JJ
particular  ||| S:1822 E:1833 ||| JJ
targeting  ||| S:1833 E:1843 ||| NN
on  ||| S:1843 E:1846 ||| IN
interferon  ||| S:1846 E:1857 ||| JJ
alpha ||| S:1857 E:1862 ||| NN
,  ||| S:1862 E:1864 ||| ,
interleukin  ||| S:1864 E:1876 ||| CD
6 ||| S:1876 E:1877 ||| CD
,  ||| S:1877 E:1879 ||| ,
B  ||| S:1879 E:1881 ||| NNP
cell  ||| S:1881 E:1886 ||| NN
CD22  ||| S:1886 E:1891 ||| NN
and  ||| S:1891 E:1895 ||| CC
C5  ||| S:1895 E:1898 ||| CD
complement  ||| S:1898 E:1909 ||| JJ
component ||| S:1909 E:1918 ||| NN
.  ||| S:1918 E:1920 ||| .
